CDNA | Ticker Profile - Titan Protect

CDNA

CareDx, Inc.

Healthcare · Diagnostics & Research · NGM

$22.25

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.1B

Total market value of the company

Trailing P/E

N/A

Forward P/E

19.54

Based on estimated future earnings — lower means cheaper

Rev Growth

+39.0%

Year-over-year revenue change

Profit Margin

-2.0%

How much profit the company keeps from each dollar of revenue

ROE

-2.4%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$26.00

+17% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 5 analysts covering this stock

About CareDx, Inc.

CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.

https://caredx.com

Country: United States Employees: 761 Industry: Diagnostics & Research

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.739

Good returns relative to risk taken

Kelly Fraction

0.0629

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.456

Drawdown risk outweighs the returns — higher risk profile

Annual Return

30.1%

Historical annualised return based on price data

Max Drawdown

-66.0%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

2.49

Significantly more volatile than the market

52W High

$23.24

4% below the year high

52W Low

$10.96

103% above the year low

Avg Volume

687,367

Average daily shares traded — higher means easier to buy and sell

Short Ratio

8.2

Days it would take all short sellers to cover — higher means more crowded

Short % Float

12.8%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.16

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

7.81

Heavy leverage — higher financial risk if revenues decline

Current Ratio

3.40

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

2.93

Like current ratio but excludes inventory — stricter test

Gross Margin

68.9%

Revenue left after cost of goods — higher means pricing power

Operating Margin

1.5%

Profit from core operations before interest and tax

Free Cash Flow

$70M

Positive — the business generates more cash than it spends

Revenue (TTM)

$413M

Total revenue over the last 12 months

Net Income

$-8,192,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$28.00

Target Median

$26.00

Target Low

$21.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go